Please login to the form below
ozanimod
This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK,
Latest news
-
BMS’ Zeposia gains FDA approval in ulcerative colitis
The FDA has approved Zeposia ( ozanimod) for the treatment of the chronic inflammatory bowel disease based on data from the phase 3 True North study.
-
J&J’s MS drug ponesimod receives approval in the US
In March 2020, the FDA also approved Bristol Myers Squibb’s (BMS) own S1P receptor modulator Zeposia ( ozanimod) for the treatment of adults with relapsing forms of MS.
-
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel).
-
Novartis builds its case for novel MS treatment ofatumumab
That competition paves the way for new entries, including Novartis’ ofatumumab and Bristol-Myers Squibb’s oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod which is also currently under review with
-
BMS suspends new clinical trials as COVID-19 cases rise in US
That includes an FDA decision on multiple sclerosis therapy ozanimod, which was due yesterday, and a verdict due by 4 April for Reblozyl (luspatercept) as a second-line therapy for anaemia
BMS’ Zeposia gains FDA approval in ulcerative colitis
J&J’s MS drug ponesimod receives approval in the US
Novartis builds its case for novel MS treatment ofatumumab
More from news
Approximately 4 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
-
20 for 2020 – Five pharma companies to watch
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
-
Pharma deals in July 2015
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
Cortellis Drugs to Watch in 2020 report
20 for 2020 – Five pharma companies to watch
Pharma deals in July 2015
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Competitive salary offered
-
CEO, Head of Health, UK
-
Six figure salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- Valneva COVID-19 vaccine more effective than AZ
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- Reckitt to spin-off pharma unit as Indivior
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
